GERN Jan 2026 0.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:39PM EDT. Market open.
| Previous close | 3.1000 |
| Open | 3.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 0.50 |
| Expiry date | 2026-01-16 |
| Day's range | 3.1000 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksGeron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of 10% and 102.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireGeron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif., May 02, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.
© 2024 Yahoo. All rights reserved.